RU2662667C2 - Вакцины на основе нуклеопротеина вируса гриппа - Google Patents

Вакцины на основе нуклеопротеина вируса гриппа Download PDF

Info

Publication number
RU2662667C2
RU2662667C2 RU2015140603A RU2015140603A RU2662667C2 RU 2662667 C2 RU2662667 C2 RU 2662667C2 RU 2015140603 A RU2015140603 A RU 2015140603A RU 2015140603 A RU2015140603 A RU 2015140603A RU 2662667 C2 RU2662667 C2 RU 2662667C2
Authority
RU
Russia
Prior art keywords
influenza
antigen
seq
nucleoprotein
imx313t
Prior art date
Application number
RU2015140603A
Other languages
English (en)
Russian (ru)
Other versions
RU2015140603A (ru
Inventor
КАМПО АСКАРАТЕЙЛЬ Жюдит ДЕЛЬ
Фергаль ИЛЛЬ
Original Assignee
Озивакс Сас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Озивакс Сас filed Critical Озивакс Сас
Publication of RU2015140603A publication Critical patent/RU2015140603A/ru
Application granted granted Critical
Publication of RU2662667C2 publication Critical patent/RU2662667C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2015140603A 2013-03-18 2014-03-18 Вакцины на основе нуклеопротеина вируса гриппа RU2662667C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305320 2013-03-18
EP13305320.7 2013-03-18
PCT/EP2014/055438 WO2014147087A1 (en) 2013-03-18 2014-03-18 Influenza nucleoprotein vaccines

Publications (2)

Publication Number Publication Date
RU2015140603A RU2015140603A (ru) 2017-04-21
RU2662667C2 true RU2662667C2 (ru) 2018-07-26

Family

ID=48044708

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015140603A RU2662667C2 (ru) 2013-03-18 2014-03-18 Вакцины на основе нуклеопротеина вируса гриппа

Country Status (11)

Country Link
US (2) US9243047B2 (enExample)
EP (1) EP2976357B1 (enExample)
JP (1) JP2016520534A (enExample)
KR (1) KR102379951B1 (enExample)
CN (2) CN105143251B (enExample)
AU (1) AU2014234363B2 (enExample)
BR (1) BR112015023738B8 (enExample)
CA (1) CA2901888C (enExample)
MX (1) MX363149B (enExample)
RU (1) RU2662667C2 (enExample)
WO (1) WO2014147087A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677799C2 (ru) * 2012-12-11 2019-01-21 Озивакс Сас Модифицированные суперспиральные белки с улучшенными свойствами
US20220184200A1 (en) * 2019-03-21 2022-06-16 Georgia State University Research Foundation, Inc. Virus-like particles and uses thereof
WO2023025864A1 (en) 2021-08-24 2023-03-02 Osivax Immunogenic compositions and their use
JP2024545462A (ja) 2021-12-22 2024-12-06 オシバックス ワクチン組成物及びそれらの使用
CA3253732A1 (en) 2022-03-22 2023-09-28 Osivax mRNA VACCINE COMPOSITIONS AND THEIR USE
CN115779079B (zh) * 2022-10-01 2026-05-05 中国人民解放军军事科学院军事医学研究院 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白
CN117659138B (zh) * 2023-12-25 2025-04-08 华中农业大学 一种流感病毒np蛋白突变体及其应用
CN121427967B (zh) * 2025-12-24 2026-06-23 威瑞生物科技(昆明)有限责任公司 一种h5n1核蛋白原核表达载体及其进行核蛋白诱导表达的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062819A2 (en) * 2005-11-30 2007-06-07 Imaxio Multimeric complexes of antigens and an adjuvant
WO2011045612A1 (en) * 2009-10-16 2011-04-21 Isis Innovation Limited Mycobacterial vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
WO1999012036A1 (en) * 1997-09-04 1999-03-11 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
WO2004016283A2 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
AU2004263387A1 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a C4bp core protein and a monomeric antigen, and its use
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
RU2677799C2 (ru) * 2012-12-11 2019-01-21 Озивакс Сас Модифицированные суперспиральные белки с улучшенными свойствами

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062819A2 (en) * 2005-11-30 2007-06-07 Imaxio Multimeric complexes of antigens and an adjuvant
WO2011045612A1 (en) * 2009-10-16 2011-04-21 Isis Innovation Limited Mycobacterial vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OGUN SOLABOMI A ET AL: "The oligomerization domain of C4-binding protein( C4bp)acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria", Infection and immunity,01.08.2008, vol.76, no.8, pp.3817-3823. *
SPENCER A.ET ALL:" Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances it immunogenicity in both mice and non-human primates" plos one, vol.7, no.3,03.08.2012,pp.2-7. *
ДУПЛИК Н.В. и др. Рекомбинантные полипептиды на основе С5а пептидазы как потенциальные компоненты вакцин против стрептококка группы B., Медицинская иммунология, т.13 N1, 2011, стр.41-48. *

Also Published As

Publication number Publication date
MX2015013304A (es) 2015-12-15
CN105143251A (zh) 2015-12-09
WO2014147087A1 (en) 2014-09-25
RU2015140603A (ru) 2017-04-21
CA2901888C (en) 2023-06-20
MX363149B (es) 2019-03-11
US20150098958A1 (en) 2015-04-09
EP2976357B1 (en) 2018-10-17
BR112015023738B1 (pt) 2023-01-10
KR20150131292A (ko) 2015-11-24
CN105143251B (zh) 2021-05-11
US9963490B2 (en) 2018-05-08
JP2016520534A (ja) 2016-07-14
CA2901888A1 (en) 2014-09-25
EP2976357A1 (en) 2016-01-27
AU2014234363B2 (en) 2018-02-15
US9243047B2 (en) 2016-01-26
KR102379951B1 (ko) 2022-03-31
US20160215032A1 (en) 2016-07-28
BR112015023738A2 (pt) 2017-11-21
AU2014234363A1 (en) 2015-09-03
CN113307881A (zh) 2021-08-27
BR112015023738B8 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
EP2976357B1 (en) Influenza nucleoprotein vaccines
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
AU2005248361B2 (en) Influenza virus vaccine composition and methods of use
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
Deng et al. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge
JP2014505681A (ja) 改変インフルエンザヘマグルチニンタンパク質およびその使用
AU2007239354A1 (en) N protein fusion proteins of a virus in the Paramyxoviridae-protein of interest family
JP2023525050A (ja) キメラインフルエンザワクチン
CN117693359A (zh) 作为免疫原的广泛反应性病毒抗原、其组合物和使用方法
Baranowska et al. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8+-mediated cross protection against influenza
WO2011056802A1 (en) Influenza virus recombinant proteins
WO2020172365A1 (en) Broadly reactive immunogens of h5 influenza virus, compositions and methods of use thereof
EP3202780A1 (en) Fusion protein comprising the n protein of a virus of the pneumovirinae subfamily
RU2571944C1 (ru) Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
RU2855931C1 (ru) Химерные вакцины против гриппа
US20260007736A1 (en) Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
US20260034205A1 (en) Modified live attenuated flu virus vaccines and uses thereof
WO2025179103A9 (en) Pentavalent and octavalent influenza virus immunogens, compositions and methods of use thereof
HK40085361A (en) Chimeric influenza vaccines
CN112955171A (zh) 产生广泛反应、泛表位的免疫原、组合物的方法及其使用方法
YE et al. RAPID DEVELOPMENT OF A VAXFECTIN®-ADJUVANTED DNA VACCINE ENCODING PANDEMIC SWINE-ORIGIN INFLUENZA A VIRUS (H1N1) HEMAGGLUTININ

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant